Literature DB >> 15452241

Cyclin-dependent kinase activity is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122-123 and UL37 immediate-early transcripts and at later times for virus production.

Veronica Sanchez1, Anita K McElroy, Judy Yen, Sama Tamrakar, Charles L Clark, Rachel A Schwartz, Deborah H Spector.   

Abstract

Human cytomegalovirus (HCMV) infection leads to dysregulation of multiple cell cycle-regulatory proteins. In this study, we examined the effects of inhibition of cyclin-dependent kinase (cdk) activity on viral replication. With the drug Roscovitine, a specific inhibitor of cyclin-dependent kinases 1, 2, 5, 7, and 9, we have shown that during the first 6 h of infection, cyclin-dependent kinase-dependent events occurred that included the regulated processing and accumulation of the immediate-early (IE) UL122-123 transcripts and UL36-37 transcripts. Altered processing of UL122-123 led to a loss of IE1-72 and an increase in IE2-86. The ratio of spliced to unspliced UL37 transcripts also changed. These effects did not require de novo protein synthesis or degradation of proteins by the proteasome. Addition of Roscovitine at the beginning of the infection was also associated with inhibition of expression of selected viral early gene products, viral DNA replication, and late viral gene expression. When Roscovitine was added after the first 6 h of infection, the effects on IE gene expression were no longer observed and viral replication proceeded through the late phase, but viral titers were reduced. The reduction in viral titer was observed even when Roscovitine was first added at 48 h postinfection, indicating that cyclin-dependent kinase activity is required at both IE and late times. Flavopiridol, another specific inhibitor of cyclin-dependent kinases, had similar effects on IE and early gene expression. These results underscore the importance of accurate RNA processing and reiterate the significant role of cell cycle-regulatory factors in HCMV infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15452241      PMCID: PMC521808          DOI: 10.1128/JVI.78.20.11219-11232.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  72 in total

1.  RNA polymerase II is aberrantly phosphorylated and localized to viral replication compartments following herpes simplex virus infection.

Authors:  S A Rice; M C Long; V Lam; C A Spencer
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

2.  Human cytomegalovirus inhibits cellular DNA synthesis and arrests productively infected cells in late G1.

Authors:  W A Bresnahan; I Boldogh; E A Thompson; T Albrecht
Journal:  Virology       Date:  1996-10-01       Impact factor: 3.616

3.  The acidic domain of the human cytomegalovirus UL37 immediate early glycoprotein is dispensable for its transactivating activity and localization but is not for its synergism.

Authors:  H Zhang; H O al-Barazi; A M Colberg-Poley
Journal:  Virology       Date:  1996-09-15       Impact factor: 3.616

4.  Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest.

Authors:  F M Jault; J M Jault; F Ruchti; E A Fortunato; C Clark; J Corbeil; D D Richman; D H Spector
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

5.  Human cytomegalovirus elevates levels of the cellular protein p53 in infected fibroblasts.

Authors:  P Muganda; O Mendoza; J Hernandez; Q Qian
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

6.  Eleven loci encoding trans-acting factors are required for transient complementation of human cytomegalovirus oriLyt-dependent DNA replication.

Authors:  G S Pari; D G Anders
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

7.  Four of eleven loci required for transient complementation of human cytomegalovirus DNA replication cooperate to activate expression of replication genes.

Authors:  A C Iskenderian; L Huang; A Reilly; R M Stenberg; D G Anders
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

8.  Expression of human cytomegalovirus UL36 and UL37 genes is required for viral DNA replication.

Authors:  J A Smith; G S Pari
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

9.  Interaction of the 72-kilodalton human cytomegalovirus IE1 gene product with E2F1 coincides with E2F-dependent activation of dihydrofolate reductase transcription.

Authors:  M J Margolis; S Pajovic; E L Wong; M Wade; R Jupp; J A Nelson; J C Azizkhan
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

10.  The retinoblastoma gene product negatively regulates transcriptional activation mediated by the human cytomegalovirus IE2 protein.

Authors:  K S Choi; S J Kim; S Kim
Journal:  Virology       Date:  1995-04-20       Impact factor: 3.616

View more
  50 in total

1.  Human cytomegalovirus inhibition by cardiac glycosides: evidence for involvement of the HERG gene.

Authors:  Arun Kapoor; Hongyi Cai; Michael Forman; Ran He; Meir Shamay; Ravit Arav-Boger
Journal:  Antimicrob Agents Chemother       Date:  2012-07-09       Impact factor: 5.191

2.  Effect of cell culture conditions on the anticytomegalovirus activity of maribavir.

Authors:  Sunwen Chou; Laura C Van Wechel; Gail I Marousek
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

3.  Nuclear export of the human cytomegalovirus tegument protein pp65 requires cyclin-dependent kinase activity and the Crm1 exporter.

Authors:  Veronica Sanchez; Jeffrey A Mahr; Nicole I Orazio; Deborah H Spector
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

4.  Human cytomegalovirus early protein pUL21a promotes efficient viral DNA synthesis and the late accumulation of immediate-early transcripts.

Authors:  Anthony R Fehr; Dong Yu
Journal:  J Virol       Date:  2010-11-03       Impact factor: 5.103

5.  Nuclear trafficking of the human cytomegalovirus pp71 (ppUL82) tegument protein.

Authors:  Weiping Shen; Elizabeth Westgard; Liqun Huang; Michael D Ward; Jodi L Osborn; Nha H Chau; Lindsay Collins; Benjamin Marcum; Margaret A Koach; Jennifer Bibbs; O John Semmes; Julie A Kerry
Journal:  Virology       Date:  2008-04-18       Impact factor: 3.616

6.  Human cytomegalovirus infection induces specific hyperphosphorylation of the carboxyl-terminal domain of the large subunit of RNA polymerase II that is associated with changes in the abundance, activity, and localization of cdk9 and cdk7.

Authors:  Sama Tamrakar; Anokhi J Kapasi; Deborah H Spector
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

7.  Cyclin-dependent Kinases Phosphorylate the Cytomegalovirus RNA Export Protein pUL69 and Modulate Its Nuclear Localization and Activity.

Authors:  Sabine Rechter; Gillian M Scott; Jan Eickhoff; Katrin Zielke; Sabrina Auerochs; Regina Müller; Thomas Stamminger; William D Rawlinson; Manfred Marschall
Journal:  J Biol Chem       Date:  2009-01-29       Impact factor: 5.157

8.  Recruitment of cdk9 to the immediate-early viral transcriptosomes during human cytomegalovirus infection requires efficient binding to cyclin T1, a threshold level of IE2 86, and active transcription.

Authors:  Anokhi J Kapasi; Charles L Clark; Karen Tran; Deborah H Spector
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

9.  Establishment of a cell-based assay for screening of compounds inhibiting very early events in the cytomegalovirus replication cycle and characterization of a compound identified using the assay.

Authors:  Yoshiko Fukui; Keiko Shindoh; Yumiko Yamamoto; Shin Koyano; Isao Kosugi; Toyofumi Yamaguchi; Ichiro Kurane; Naoki Inoue
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

10.  Cell cycle-independent expression of immediate-early gene 3 results in G1 and G2 arrest in murine cytomegalovirus-infected cells.

Authors:  Lüder Wiebusch; Anke Neuwirth; Linus Grabenhenrich; Sebastian Voigt; Christian Hagemeier
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.